| Phytochemical Name : Etilevodopa |
| PCNDIDE0101 |
| Pubchem CID : 170345 |
| Molecular formula: C11H15NO4 |
| Canonical SMILES : CCOC(=O)C(CC1=CC(=C(C=C1)O)O)N |
Synonymes : Etilevodopa|37178-37-3|L-Dopa ethyl ester|Levodopa ethyl ester|O-Ethyl-DOPA|TV-1203|ethyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate|Etilevodopa [USAN:INN]|Ethyl (S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate|UNII-895X917GYE|895X917GYE|L-Tyrosine, 3-hydroxy-, ethyl ester|(S)-ETHYL 2-AMINO-3-(3,4-DIHYDROXYPHENYL)PROPANOATE|(-)-3,4-Dihydroxy-L-phenylalanine, ethyl ester|3-hydroxy-L-tyrosine ethyl ester|L-DOPA ethyl ester;Levodopa ethyl ester|Levodopa-ethyl-ester|MFCD00871210|LDEE|3,4-Dihydroxy-L-phenylalanine ethyl ester|ETILEVODOPA [INN]|Etilevodopa (USAN/INN)|ETILEVODOPA [USAN]|D06SEY|ETILEVODOPA [WHO-DD]|SCHEMBL584493|CHEMBL1823681|DTXSID10905092|CHEBI:135971|2(S)-Amino-3-(3,4-dihydroxyphenyl)propionic acid ethyl ester|763906-29-2|3-HYDROXY-TYROSINE ETHYL ESTER|AKOS010395756|AKOS015933284|CCG-221888|DB06535|ND-0601|L-Dopa ethyl ester, >=98% (HPLC)|NCGC00408874-03|HY-116016|CS-0063515|D04097|EN300-150307|F52325|Levodopa prodrug (transdermal, Parkinson's disease)|Q5404593|L-DOPA prodrug (transdermal, Parkinson's disease), NeuroDerm|Levodopa ester, (transdermal, Parkinson's disease), NeuroDerm|Levodopa prodrug (transdermal, Parkinson's disease), NeuroDerm|(S)-Ethyl 2-amino-3-(3,4-dihydroxyphenyl)propanoate (H-L-Tyr(3-OH)-OEt)|3718-37-4 |
| Structure | |
| 3D structure | 2D structure |
 |
| Log Po/w (iLOGP) : 1.770 |
| Log Po/w (XLOGP3) : 0.280 |
| Log Po/w (WLOGP) : 0.530 |
| Log Po/w (MLOGP) : 0.550 |
| Log Po/w (SILICOS-IT) : 0.820 |
| Consensus Log Po/w : 0.790 |